

James B Wetmore

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7841776/james-b-wetmore-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

87
papers

1,663
citations

20
h-index

38
g-index

99
ext. papers

2,238
ext. citations

5.4
avg, IF

4.84
L-index

#	Paper	IF	Citations
87	AuthorsRRReply.. <i>Journal of the American Society of Nephrology: JASN</i> , 2022 , 33, 455-457	12.7	
86	Adverse Outcomes Associated With Off-Label Agents Used to Treat Dementia Patients With Psychosis: A Case-Control Medicare Database Study.. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022 , 37, 15333175221081374	2.5	0
85	Medicare claims analysis of agents used to manage dementia-related psychosis: a treatment pattern study.. <i>International Clinical Psychopharmacology</i> , 2022 , 37, 84-91	2.2	
84	CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort.. <i>Kidney360</i> , 2022 , 3, 435-445	1.8	0
83	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.. <i>Nature Reviews Nephrology</i> , 2022 ,	14.9	4
82	Sequential Bone Scintigraphy and the Evolution of Warfarin-Mediated Calcific Uremic Arteriolopathy. <i>Case Reports in Nephrology and Dialysis</i> , 2021 , 11, 78-86	1.3	0
81	Initial Effects of COVID-19 on Patients with ESKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 1444-1453	12.7	19
80	Testing Patterns for CKD-MBD Abnormalities in a Sample US Population. <i>Kidney International Reports</i> , 2021 , 6, 1141-1150	4.1	1
79	Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 826-839	4.3	8
78	Association of Dementia-Related Psychosis With Long-term Care Use and Death. <i>Neurology</i> , 2021 , 96, e1620-e1631	6.5	4
77	COVID-19-Associated Decline in the Size of the End-Stage Kidney Disease Population in the United States. <i>Kidney International Reports</i> , 2021 , 6, 2698-2701	4.1	3
76	CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 180-189	7.4	3
75	Changes in Treatment of Patients with Incident ESKD during the Novel Coronavirus Disease 2019 Pandemic. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , 32, 2948-2957	12.7	8
74	Pragmatic clinic randomized trial to improve chronic kidney disease care: Design and adaptation due to COVID disruptions. <i>Contemporary Clinical Trials</i> , 2021 , 109, 106501	2.3	1
73	Development and outcomes of hyperkalemia in hospitalized patients: potential implications for care. <i>American Heart Journal</i> , 2021 , 241, 59-67	4.9	
72	Changes in hemodialysis catheter management after introduction of the end-stage renal disease prospective payment system. <i>BMC Nephrology</i> , 2021 , 22, 8	2.7	0
71	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. <i>Stroke</i> , 2020 , 51, 2364-2373	6.7	14

70	Association of hospital transfusion use and infection-related rehospitalizations among patients receiving hemodialysis: A retrospective cohort study. <i>Hemodialysis International</i> , 2020 , 24, 79-88	1.7	
69	Factors Associated with Elective Withdrawal of Maintenance Hemodialysis: A Case-Control Analysis. <i>American Journal of Nephrology</i> , 2020 , 51, 227-236	4.6	2
68	Secondary Hyperparathyroidism and Hyperphosphatemia. <i>Nephrology Self-assessment Program: NephSAP</i> , 2020 , 19, 206-214	0	
67	Response by Wetmore et al to Letter Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". <i>Stroke</i> , 2020 , 51, e363-e364 ⁰	6.7	0
66	Outcomes Following Ischemic Stroke in Older Patients With CKD Stages 4 and 5: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 784-793	7.4	4
65	Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. <i>BMC Endocrine Disorders</i> , 2019 , 19, 89	3.3	7
64	Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters. <i>American Journal of Nephrology</i> , 2019 , 49, 225-232	4.6	7
63	Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. <i>BMC Nephrology</i> , 2019 , 20, 85	2.7	13
62	Early withdrawal and non-withdrawal death in the months following hemodialysis initiation: A retrospective cohort analysis. <i>Hemodialysis International</i> , 2019 , 23, 261-272	1.7	5
61	Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019 , 68, 95-101	3.6	8
60	Low Quality of International Classification of Diseases, 10th Revision, Procedural Coding System Data Undermines the Validity of the Standardized Transfusion Ratio: Time to Chart a New Course?. <i>Advances in Chronic Kidney Disease</i> , 2019 , 26, 237-249	4.7	
59	Dialysis and End-Stage Kidney Disease: Epidemiology, Costs, and Outcomes 2019 , 311-338.e4		1
58	Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis. <i>American Journal of Cardiology</i> , 2019 , 123, 598-604	3	2
57	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018 , 39, 2314-2325	9.5	104
56	Readmissions Following a Hospitalization for Cardiovascular Events in Dialysis Patients: A Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	9
55	Factors Associated With Withdrawal From Maintenance Dialysis: A Case-Control Analysis. <i>American Journal of Kidney Diseases</i> , 2018 , 71, 831-841	7.4	18
54	Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients. <i>Annals of Transplantation</i> , 2018 , 23, 224-231	1.4	6
53	Insights From the 2016 Peer Kidney Care Initiative Report: Still a Ways to Go to Improve Care for Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2018 , 71, 123-132	7.4	17

52	Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. <i>PLoS ONE</i> , 2018 , 13, e0203767	3.7	8
51	Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 69-80	2.5	8
50	An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population. <i>Statistical Methods in Medical Research</i> , 2017 , 26, 2667-2680	2.3	1
49	A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. <i>Statistics in Medicine</i> , 2017 , 36, 4121-4140	2.3	7
48	Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy. <i>International Urology and Nephrology</i> , 2017 , 49, 2247-2256	2.3	21
47	Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study. <i>PLoS ONE</i> , 2017 , 12, e0171098	3.7	8
46	Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. <i>Clinical Epidemiology</i> , 2017 , 9, 267-277	5.9	94
45	Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. <i>Clinical Nephrology</i> , 2017 , 88, 254-265	2.1	4
44	The role of parathyroidectomy in the management of secondary hyperparathyroidism. <i>Current Opinion in Nephrology and Hypertension</i> , 2017 , 26, 516-522	3.5	7
43	Old versus new: Progress in reaching the goals of the new kidney allocation system. <i>Human Immunology</i> , 2017 , 78, 9-15	2.3	30
42	The Healthy People 2020 Objectives for Kidney Disease: How Far Have We Come, and Where Do We Need to Go?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 200-209	6.9	6
41	Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, 103-11	4.3	21
40	Geovariation in Fracture Risk among Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1413-21	6.9	14
39	The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. <i>Kidney International</i> , 2016 , 90, 853-60	9.9	27
38	Association of multiple ischemic strokes with mortality in incident hemodialysis patients: an application of multistate model to determine transition probabilities in a retrospective observational cohort. <i>BMC Nephrology</i> , 2016 , 17, 134	2.7	1
37	Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis. <i>BMC Surgery</i> , 2016 , 16, 77	2.3	4
36	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 305-13	12.7	241
35	Patient characteristics, disease burden, and medication use in stage 4 - 5 chronic kidney disease patients. <i>Clinical Nephrology</i> , 2016 , 85, 101-11	2.1	6

34	Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. <i>BMC Nephrology</i> , 2016 , 17, 53	2.7	4
33	Improving Outcomes in Patients Receiving Dialysis: The Peer Kidney Care Initiative. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1297-304	6.9	15
32	The rise of FGF23: should insights from population-based studies inform future clinical trials?. <i>Kidney International</i> , 2016 , 90, 477-9	9.9	1
31	Relationship between stroke and mortality in dialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 80-9	6.9	23
30	Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 90-7	6.9	92
29	Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. <i>American Journal of Nephrology</i> , 2015 , 41, 354-61	4.6	18
28	A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1031-40	6.9	60
27	Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015 , 10, 1021-30	6.9	55
26	The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction. <i>American Heart Journal</i> , 2015 , 170, 735-43	4.9	3
25	Association between higher rates of cardioprotective drug use and survival in patients on dialysis. <i>Research in Social and Administrative Pharmacy</i> , 2015 , 11, 824-43	2.9	6
24	Relationship between calcium channel blocker class and mortality in dialysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1249-58	2.6	9
23	Race, ethnicity, and state-by-state geographic variation in hemorrhagic stroke in dialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 756-63	6.9	15
22	Polycystic kidney disease and cancer after renal transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2335-41	12.7	43
21	Estimation of Drug Effectiveness by Modeling Three Time-dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population. <i>Statistics in Biopharmaceutical Research</i> , 2014 , 6, 229-240	1.2	6
20	Impact of a modified data capture period on Liu comorbidity index scores in Medicare enrollees initiating chronic dialysis. <i>BMC Nephrology</i> , 2013 , 14, 51	2.7	10
19	Atrial fibrillation and risk of stroke in dialysis patients. <i>Annals of Epidemiology</i> , 2013 , 23, 112-8	6.4	47
18	Stroke and the "stroke belt" in dialysis: contribution of patient characteristics to ischemic stroke rate and its geographic variation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013 , 24, 2053-61	12.7	27
17	Impact of race on cumulative exposure to antihypertensive medications in dialysis. <i>American Journal of Hypertension</i> , 2013 , 26, 234-42	2.3	5

16	Geographic variation in HMG-CoA reductase inhibitor use in dialysis patients. <i>Journal of General Internal Medicine</i> , 2012 , 27, 1475-83	4	4
15	Painless myocardial ischemia is associated with mortality in patients with chronic kidney disease. <i>Nephron Clinical Practice</i> , 2012 , 122, 9-16		6
14	The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. <i>Kidney International</i> , 2012 , 81, 469-76	9.9	67
13	Association of race with cumulative exposure to statins in dialysis. <i>American Journal of Nephrology</i> , 2012 , 36, 90-6	4.6	7
12	Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2011 , 58, 73-83	7.4	21
11	Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis. <i>BMC Research Notes</i> , 2011 , 4, 542	2.3	6
10	Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E57-64	5.6	17
9	Association of decreased glomerular filtration rate with racial differences in survival after acute myocardial infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 733-40	6.9	3
8	Role of lean body mass in estimating glomerular filtration rate in Alzheimer disease. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 2222-31	4.3	6
7	Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 110-6	6.9	118
6	Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 198-205	4.3	15
5	Discrepancies between creatinine- and cystatin C-based equations: implications for identification of chronic kidney disease in the general population. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010 , 44, 242-50		10
4	Review: insufficient evidence exists on the benefit of vitamin D in patients with chronic kidney disease not requiring dialysis. <i>Annals of Internal Medicine</i> , 2010 , 152, JC4-12	8	
3	Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. <i>Nature Clinical Practice Nephrology</i> , 2009 , 5, 24-33		44
2	The ABCs of cardioprotection in dialysis patients: a systematic review. <i>American Journal of Kidney Diseases</i> , 2009 , 53, 457-66	7.4	29
1	Oral paricalcitol: a viewpoint by James B. Wetmore and L. Darryl Quarles. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006 , 5, 326-7		